Quick View
| Metric | Current Period | Same Period Last Year | YoY |
|---|---|---|---|
| Revenue | ¥110.2B | ¥108.4B | +1.6% |
| Operating Income | ¥3.6B | ¥6.2B | −41.5% |
| Ordinary Income | ¥3.2B | ¥5.8B | −45.2% |
| Net Income | ¥2.4B | ¥4.7B | −49.4% |
| ROE | 1.8% | 3.6% | - |
Executive Summary
In FY2026 Q3, Revenue was ¥110.2B (YoY +¥1.8B +1.6%), a modest increase, while Operating Income was ¥3.6B (YoY -¥2.6B -41.5%), Ordinary Income ¥3.2B (YoY -¥2.6B -45.2%), and Net Income ¥2.4B (YoY -¥2.3B -49.4%), resulting in a substantial decline in profits. With Revenue nearly flat, higher cost of goods sold ratio and increased interest burden (interest expenses doubled from ¥0.5B to ¥1.06B) significantly compressed profitability. The Operating Margin fell to 3.3% (down -2.4pt from 5.7% last year), well below industry levels, making structural profitability improvement an urgent priority.
Key Financial Metrics
[Profitability] ROE 1.8% (down from 3.6% last year), Operating Margin 3.3% (down -2.4pt from 5.7% last year), Net Margin 2.2% (down -2.1pt from 4.3% last year), and Gross Margin 18.7%, indicating that a high cost of goods sold ratio is squeezing earnings. [Cash Quality] Cash and deposits of ¥10.1B versus short-term debt of ¥35.2B imply a cash coverage of 0.29x, indicating thin liquidity. [Investment Efficiency] Total Asset Turnover 0.40x; interest burden coefficient 0.786, with interest accounting for about 21% of profit, a high level. [Financial Soundness] Equity Ratio 48.6%, Current Ratio 162.1%, interest-bearing debt ¥77.2B (short-term borrowings ¥35.2B, long-term borrowings ¥42.0B) with a short-term debt ratio of 45.6%, warranting attention to refinancing risk. Debt-to-Equity Ratio 1.06x; Financial Leverage 2.06x.
Cash Flow Analysis
Cash and deposits increased by ¥0.4B YoY to ¥10.1B, a limited increase. Cash coverage relative to short-term borrowings of ¥35.2B is only 0.29x, indicating a thin liquidity buffer for short-term debt repayment/refinancing. Inventories comprise finished goods ¥62.5B, raw materials ¥18.0B, and work-in-process ¥2.3B, totaling ¥82.8B, with finished goods notably tying up capital. Accounts receivable stands at ¥30.3B, down YoY, indicating improving collection efficiency, but inventory tie-up continues to squeeze working capital efficiency. Of the ¥77.2B in interest-bearing debt, short-term borrowings account for ¥35.2B or 45.6%, and refinancing risk and interest burden (interest expenses ¥1.06B, up +¥0.56B YoY) are affecting cash management.
Quality of Earnings
Against Ordinary Income of ¥3.2B, Operating Income was ¥3.6B, resulting in a net non-operating expense burden of about ¥0.5B. While dividend income of ¥0.56B contributes, interest expenses of ¥1.06B are large, with interest burden compressing non-operating income. Interest expenses have doubled from ¥0.50B last year, reflecting pronounced impacts from rising rates and higher borrowings. Non-operating income is limited to about 0.5% of revenue, leaving the core reliance on operating activities; however, with an Operating Margin of 3.3%, the weakness of core operating profitability is an issue. As there is no disclosure of Operating Cash Flow, we cannot directly verify the cash realization quality of earnings, but the significant inventory build and rising interest burden raise concerns about deteriorating cash conversion efficiency.
Risk Factors
(1) Liquidity Risk: With cash and deposits of ¥10.1B versus short-term borrowings of ¥35.2B, cash coverage is 0.29x; liquidity for short-term debt repayment/refinancing is thin, and in a rising rate environment, cash flow could be pressured. (2) Profitability Deterioration Risk: The Operating Margin is a low 3.3%, with rising cost of goods sold ratio and higher interest burden squeezing profits. Of ¥16.98B in SG&A, director compensation is ¥4.07B, indicating a heavy fixed cost burden; with sluggish sales growth, profitability may deteriorate further. (3) Inventory-Related Risk: Finished goods inventory is a sizable ¥62.5B, raising not only obsolescence and impairment risks but also concerns about capital tie-up worsening working capital efficiency.
Industry Benchmark (Reference; Our Research)
[Positioning in Industry] (Reference information; our research) In a benchmark comparison within the manufacturing sector for FY2025 Q3, the company’s financial indicators are well below the industry median. Profitability: The 3.3% Operating Margin is -4.0pt below the industry median of 7.3% (IQR: 4.6%–12.0%), and the 2.2% Net Margin is -3.2pt below the industry median of 5.4% (IQR: 3.5%–8.9%). ROE at 1.8% is far below the industry median of 4.9% (IQR: 2.8%–8.2%), highlighting low capital efficiency. Soundness: The 48.6% Equity Ratio is below the industry median of 63.9% (IQR: 51.5%–72.3%), and the Current Ratio of 1.62x is well below the industry median of 2.67x (IQR: 2.00–3.56x). Efficiency: Sales growth of +1.6% is slightly below the industry median of +2.8%, indicating a limited growth pace. The company ranks in the lower tier of the industry in terms of profitability and financial soundness, with particular need to improve Operating Margin and ROE. (*Industry: Manufacturing (n=65 companies); Comparison: FY2025 Q3; Source: Our compilation)
Key Takeaways from Results
(1) Significant Margin Deterioration and Higher Interest Burden: The Operating Margin worsened by -2.4pt from 5.7% last year to 3.3%, and interest expenses doubled (¥0.50B → ¥1.06B). A fundamental overhaul of the earnings structure and a review of borrowing terms are in focus. (2) High Payout Ratio and Sustainability: Against a full-year dividend forecast of ¥10, the Payout Ratio based on current-period Net Income is approximately 83%, a high level; with no Operating Cash Flow disclosure, the sustainability of maintaining dividends is a focal point. (3) Inventory Levels and Working Capital Efficiency: Finished goods inventory of ¥62.5B represents significant capital tie-up. There is room to improve inventory turnover and working capital efficiency, putting upcoming inventory reduction measures and cash generation capacity in the spotlight.
This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not constitute a recommendation to invest in any particular security. The industry benchmarks are reference information compiled by our firm based on publicly available financial statements. Make investment decisions at your own responsibility and, as necessary, consult a professional advisor.
AI Financial Analysis
Executive Summary
FY2026 Q3 performance was weak: modest sales growth did not offset substantial margin compression, higher financing costs, and the absence of prior-year extraordinary income. Revenue increased 1.6% year on year to ¥11.02bn. Operating income fell 41.5% to ¥364m, ordinary income declined 45.2% to ¥318m, and net income decreased 49.4% to ¥238m. The operating margin contracted by 245 basis points to 3.3% from 5.7% in the prior-year nine-month period. Gross margin declined by 144 basis points to 18.7% from 20.2%, indicating that production and procurement costs rose faster than sales. SG&A expenses increased 8.8% to ¥1.70bn, materially outpacing revenue growth despite the SG&A-to-sales ratio easing slightly to 15.4% from 14.4% because of the lower gross-profit base. R&D expenditure rose 16.7% to ¥461m, equivalent to 4.2% of revenue and 127% of reported operating income. Directors' compensation increased 12.4% to ¥407m, further raising the fixed-cost burden in a low-margin period. Interest expense more than doubled to ¥106m from ¥50m, reducing the interest burden to 0.786; thus, 21% of EBIT was absorbed by net financing costs before tax. Dividend income of ¥56m provided support to non-operating income, but it was insufficient to offset the rise in interest expense. Net income was also affected by a ¥31m loss on disposal of fixed assets, while the prior period included ¥65m of extraordinary insurance income. The effective tax rate was low at 16.8%, which partly limited the decline from pre-tax profit to net income. The balance sheet retains adequate headline liquidity, with a 162.1% current ratio and ¥4.98bn of working capital. However, cash of ¥1.01bn covered only 0.29x of short-term loans, while short-term debt represented 45.6% of interest-bearing debt, creating a meaningful refinancing and cash-management sensitivity. Operating working capital is the central operational concern: receivable days of 75, inventory days of 253, and a 255-day cash conversion cycle indicate capital is tied up for an extended period. Finished goods increased 12.9% year on year to ¥6.25bn and represented the majority of the ¥8.59bn inventory balance, raising the importance of demand conversion, pricing discipline, and inventory valuation. The full-year dividend plan is ¥10 per share, but no earnings forecast is available to establish a full-year payout ratio; preservation of cash generation and working-capital discipline will be important for dividend coverage.
Profitability Analysis
Reported annualized ROE was 2.4%, derived from a 2.2% net profit margin, 0.535x annualized asset turnover, and 2.06x financial leverage. The weakest element of the DuPont structure is profitability rather than leverage: the 2.2% net margin is below the 3% concern threshold, while leverage is moderate at 2.06x. The principal year-on-year deterioration was the operating-margin decline to 3.3% from 5.7%, a 245bp contraction that accounts for most of the earnings decline. Gross margin fell 144bp to 18.7%, below the 20% reference level, showing that cost of sales increased 3.5% versus only 1.6% sales growth. SG&A grew 8.8%, with R&D up ¥66m and directors' compensation up ¥45m; this absolute cost growth exceeded revenue growth and amplified operating leverage negatively. R&D intensity increased to 4.2% from 3.6%, which may support product development in chemical manufacturing but places near-term pressure on earnings when gross margin is weak. The tax burden was favorable at 0.832, but the interest burden of 0.786 was weak because ¥106m of interest expense consumed 21% of EBIT. Interest coverage of 3.43x is above a severe-stress level but below the 5x level associated with strong debt-servicing capacity. Annualized ROIC of 2.0% is also below 5%, indicating that the capital deployed in plant, inventory, and working capital is currently generating a low return. The profitability recovery requirement is therefore primarily a restoration of gross margin and conversion of fixed operating costs into higher volume, rather than additional balance-sheet leverage.
Growth Assessment
Revenue growth of 1.6% demonstrates that demand was broadly stable, but the growth quality was weak because operating profit declined 41.5%. Cost of sales rose 3.5%, more than twice the rate of sales growth, suggesting unfavorable product mix, input-cost pressure, under-absorption of manufacturing fixed costs, or pricing lag. Finished-goods inventory rose ¥715m year on year to ¥6.25bn, while total inventory increased ¥720m to ¥8.59bn. This inventory build substantially exceeded the ¥178m increase in nine-month revenue and requires close monitoring for sales conversion and potential margin pressure. Raw-material inventory declined 4.1% to ¥1.80bn and work in process declined 7.6% to ¥231m, whereas finished goods rose 12.9%; the pattern points to accumulation at the completed-product stage rather than an expansion of production inputs. R&D spending of ¥461m, or 4.2% of sales, is within a reasonable range for a specialty chemical manufacturer and may underpin medium-term product competitiveness. However, R&D was greater than reported operating income, so the company needs improved gross-profit generation for this investment to earn an adequate return. The revenue base also has a high working-capital intensity, as reflected in 75 annualized receivable days and 253 annualized inventory days. The 255-day annualized cash conversion cycle is materially above manufacturing reference ranges and limits the quality of top-line growth. Dividend income of ¥56m contributed to ordinary earnings but is not a substitute for improving operating profitability. The near-term outlook depends on whether the finished-goods balance can be converted into sales without incremental discounting and whether cost inflation can be passed through. No full-year revenue or earnings forecast is provided, so progress against full-year profit guidance cannot be assessed.
Financial Health
Liquidity is adequate on conventional balance-sheet measures: the current ratio and quick ratio are both 162.1%, and working capital is ¥4.98bn. Current assets of ¥13.00bn exceed current liabilities of ¥8.02bn by a meaningful margin, so there is no current-ratio warning. Solvency is moderate rather than aggressive, with debt-to-equity of 1.06x and debt-to-capital of 36.6%; neither breaches the stated high-risk thresholds of 2.0x and 60%, respectively. Total interest-bearing debt was ¥7.72bn, comprising ¥3.52bn of short-term loans and ¥4.20bn of long-term loans. Short-term debt represents 45.6% of interest-bearing debt, above the 40% refinancing-risk alert threshold. Cash and deposits of ¥1.01bn cover only 29% of short-term loans, which means the company depends on turnover of receivables and inventory, operating cash inflow, and access to bank refinancing rather than cash alone. The current portion of long-term loans increased 46.1% year on year to ¥894m, reinforcing the near-term debt-maturity management requirement. Long-term loans increased 6.5% to ¥4.20bn, while total debt increased approximately 5.7%, despite operating-profit deterioration. Interest expense rose 112% year on year, substantially faster than debt, indicating a higher effective funding cost and/or refinancing at higher rates. PPE totals ¥11.92bn, or 43.4% of assets, consistent with a capital-intensive manufacturing profile; the low 2.0% annualized ROIC makes utilization of this asset base an important issue. Investment securities increased ¥308m to ¥2.36bn and account for 8.6% of total assets, including valuation differences on securities of ¥1.12bn within equity-related reserves. Intangible assets decreased ¥36m, or 26.3%, to ¥101m, most likely reflecting amortization or disposal; at only 0.4% of assets, this movement has limited balance-sheet significance. Asset retirement obligations of ¥13m equal less than 0.1% of total liabilities, indicating no material recorded environmental-restoration burden.
Notable B/S Changes
Finished goods: +¥0.72bn (+12.9%) to ¥6.25bn - inventory accumulation materially exceeded revenue growth and heightens demand-conversion, pricing, and valuation risk. Accounts receivable: -¥0.75bn (-19.9%) to ¥3.03bn - favorable reduction in the receivables balance, although reported annualized DSO remains elevated at 75 days. Current portion of long-term loans: +¥0.28bn (+46.1%) to ¥0.89bn - increases near-term repayment or refinancing requirements. Long-term loans: +¥0.26bn (+6.5%) to ¥4.20bn - debt increased while operating profit declined, contributing to higher financing-cost sensitivity. Investment securities: +¥0.31bn (+15.0%) to ¥2.36bn - portfolio value increased and represents 8.6% of total assets, adding exposure to market-value movements. Intangible assets: -¥0.04bn (-26.3%) to ¥0.10bn - likely amortization or disposal; limited balance-sheet impact given the 0.4% asset weighting.
Cash Flow Quality
Cash-flow quality cannot be quantified because operating, investing, and financing cash-flow figures are not provided. Nonetheless, the balance-sheet movement signals elevated cash-conversion risk. Receivable days of 75 exceed the 60-day warning level, indicating slower collection than the stated benchmark. Inventory days of 253 are exceptionally long relative to the 90-day warning level for manufacturing businesses. The annualized cash conversion cycle of 255 days is well above the 120-day warning threshold, meaning a prolonged period is required to recover cash invested in production and sales. Inventory increased ¥720m year on year, led almost entirely by a ¥715m increase in finished goods. This is a potential earnings-quality concern because sales growth was only ¥178m and because future liquidation of the stock may require lower pricing or generate valuation losses if demand does not materialize. Trade receivables fell ¥751m to ¥3.03bn, which is favorable in absolute terms, but the reported annualized DSO remains elevated. Trade payables and electronically recorded operating obligations totaled ¥2.84bn, broadly supporting supplier funding, but they do not offset the scale of the finished-goods position. The combination of low cash relative to short-term debt and a long cash conversion cycle heightens dependence on disciplined inventory management. The ¥31m fixed-asset disposal loss is a non-recurring charge, equivalent to 13.0% of net income, and modestly reduces the period's reported earnings quality. Prior-year net income also benefited from ¥65m of extraordinary insurance income, so the year-on-year net-income decline includes the loss of that non-recurring benefit. OCF-to-net-income, free cash flow, capex coverage, and accrual-ratio tests cannot be calculated from the available figures.
Dividend Sustainability
The company plans a full-year dividend of ¥10 per share. Based on 21.615 million shares outstanding net of treasury stock, the indicated annual cash dividend would be approximately ¥216m. This amount equals about 91% of nine-month net income of ¥238m, although that comparison is not a full-year dividend payout ratio because earnings are cumulative through Q3. The nine-month EPS was ¥11.06, while the planned full-year dividend is ¥10 per share; therefore, dividend headroom depends on fourth-quarter profitability. No interim dividend was paid at Q2, implying that the planned distribution is likely concentrated in the year-end payment. Retained earnings were ¥5.48bn, providing a balance-sheet buffer for the stated dividend. However, cash and deposits were only ¥1.01bn against ¥3.52bn of short-term loans, and the business has a 255-day annualized cash conversion cycle. Dividend sustainability consequently depends more on operating cash release from inventory and receivables than on the current cash balance. The absence of cash-flow data prevents a direct test of free-cash-flow coverage. The absence of a full-year earnings forecast also prevents calculation of the forward dividend payout ratio. A stable ¥10 dividend would require operating-margin recovery or continued balance-sheet support if the current earnings run rate persists.
Risk Assessment
Business risks include Margin recovery risk: gross margin fell to 18.7% and operating margin to 3.3%, so additional raw-material, energy, or pricing pressure could disproportionately reduce earnings., Inventory realization risk: finished goods rose 12.9% to ¥6.25bn, and 253 annualized inventory days raise the risk of slower demand, discounting, obsolescence, or inventory valuation charges., Chemical-manufacturing risk: profitability is exposed to feedstock and energy-cost volatility, customer demand cycles, product-quality requirements, and environmental regulation., R&D return risk: R&D expenditure increased 16.7% to ¥461m while operating income declined, requiring successful commercialization and pricing to generate an adequate return..
Financial risks include Refinancing risk is elevated because 45.6% of interest-bearing debt is short term and cash covers only 0.29x of short-term loans., Interest-rate risk has increased: interest expense rose from ¥50m to ¥106m and the interest burden indicates that 21% of EBIT is consumed by interest., Debt-service flexibility is limited by 3.43x interest coverage, which is below the 5x strong-coverage benchmark., Working-capital funding risk is high because the 255-day annualized cash conversion cycle can require continued bank funding even when current-ratio liquidity appears adequate..
Key concerns include Highest priority: conversion of the finished-goods inventory build into cash without sacrificing margin., High priority: restoration of gross margin and operating margin, as revenue growth alone is currently not translating into earnings growth., High priority: management of short-term debt maturities and funding costs amid low cash relative to short-term borrowings., Medium priority: annualized ROIC of 2.0% and ROE of 2.4% indicate weak returns on the company's substantial PPE and working-capital base., Medium priority: the ¥10 per-share dividend requires close monitoring against fourth-quarter earnings and cash generation..
Investment Implications
Key takeaways include Sales rose 1.6%, but operating income fell 41.5% as gross margin compressed 144bp and operating margin compressed 245bp., The principal operating issue is the ¥6.25bn finished-goods balance and the resulting 253-day annualized inventory cycle., Balance-sheet liquidity is adequate by current ratio, but cash coverage of short-term loans is weak at 0.29x and refinancing exposure is meaningful., Higher interest expense is now material, consuming 21% of EBIT and contributing to the 45.2% decline in ordinary income., R&D intensity of 4.2% supports technology investment, but returns remain weak, with annualized ROIC of 2.0% and ROE of 2.4%..
Metrics to watch include Gross margin and operating margin, particularly the ability to recover from 18.7% and 3.3%, respectively., Finished-goods inventory, inventory days, and any inventory valuation or write-down charges., Receivable days, annualized cash conversion cycle, and operating cash flow relative to net income., Short-term debt, the current portion of long-term loans, cash-to-short-term-debt coverage, and interest coverage., Fourth-quarter earnings generation relative to the ¥10 per-share full-year dividend..
Regarding relative positioning, The company presents as a capital-intensive specialty chemical manufacturer with adequate headline liquidity but below-benchmark profitability, capital efficiency, and working-capital efficiency. Its 3.3% operating margin, 2.0% annualized ROIC, 253-day annualized inventory days, and 255-day annualized cash conversion cycle compare unfavorably with the supplied manufacturing benchmarks, while its 1.06x debt-to-equity ratio and 36.6% debt-to-capital ratio remain moderate.